Achilles Therapeutics plc
CIK 0001830749
Revenue (TTM)
—
Q2 Jun 2024
Net Income (TTM)
−$63.01M
+2.1% YoY
Q2 Jun 2024
EPS Diluted (TTM)
−$1.74
+4.4% YoY
Q2 Jun 2024
Gross Margin
—
Q2 Jun 2024
Operating Margin
—
Q2 Jun 2024
Net Margin
—
Q2 Jun 2024
Free Cash Flow (TTM)
−$49.55M
Q2 Jun 2024
Cash
$95.11M
Q2 Jun 2024
Total Debt
—
Q2 Jun 2024
Shares Outstanding
41.08M sh
Q2 Jun 2024
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.